Medicaid expansion is a key provision by which the Affordable Care Act seeks to improve access to health insurance. However, there is concern over the quality and cost of care received by Medicaid beneficiaries. We previously demonstrated that payer status predicts index care setting, which influences rates of 30-day revisits following definitive surgery for urinary stone disease. In this context, we used all-payer claims data to identify predictors of 30-day revisit and associated cost following definitive surgery for nephroureterolithiasis.
INTRODUCTION AND OBJECTIVES:
Medicaid expansion is a key provision by which the Affordable Care Act seeks to improve access to health insurance. However, there is concern over the quality and cost of care received by Medicaid beneficiaries. We previously demonstrated that payer status predicts index care setting, which influences rates of 30-day revisits following definitive surgery for urinary stone disease. In this context, we used all-payer claims data to identify predictors of 30-day revisit and associated cost following definitive surgery for nephroureterolithiasis.
METHODS: All-payer data from the 2014 Healthcare Cost and Utilization Project State Databases from Florida and New York were used to identify all index elective definitive surgical interventions for nephroureterolithiasis in the form of ureteroscopy (URS) or shockwave lithotripsy (SWL). Patient demographics, regional data, 30-day revisit rates, and total charges (converted to costs) associated with revisits were determined. Multivariate logistic regression adjusted for facility clustering was utilized to identify predictors of re-intervention following definitive therapy for nephroureterolithiasis.
RESULTS: Of the 27,527 unique patients undergoing either an elective index URS (n[16, 572) The present study was aimed to evaluate the surgical outcomes at 17 years after the Tensionfree Vaginal Tape (TVT) surgery which was performed to manage females with stress urinary incontinence (SUI).
METHODS: Among 110 women with SUI who underwent the TVT procedure between March 1999 and December 2000, 51 patients were followed up for at least 17 years postoperatively. Preoperative evaluation of the patients was performed with history taking, physical examinations, one-hour pad tests, urine analysis, urine cultures and complete multichannel urodynamic studies. Long-term evaluations were performed via questionnaires on the durability of the surgical outcome and the patients' satisfaction with the procedure. All the patients were asked about their voiding symptoms as well as any recurrence by conducting detailed telephone interviews.
RESULTS: The mean follow-up period was 207.62 AE 8.46 months. Of the 51 patients who were followed up for at least 17 years, the patients were classified according to their symptom grades; grade I (n[13, 25.49%), grade II (n[28, 54.90%) and grade III (n[10, 19.61%). The TVT procedure remained successful in 42 patients (82.35%): SUI was remained cured in 28 patients (54.90%) and improved in 14 patients (27.45%) while recurred incontinence was observed in 9 patients (17.65%). According to the telephone interviews, 26 patients (50.98%) were very satisfied and 16 patients (31.37%) were satisfied with the TVT procedure. However, 6 (11.76%) and 3 (5.88%) patients answered 'tolerable' and 'dissatisfied', respectively, and all of these patients had recurred SUI. Among the investigated patients, no serious or long-term complications related to the procedure were observed.
The Food and Drug Administration (FDA) issued a 2011 warning on serious complications of surgical mesh in urogynecological procedures. There is limited data on the impact of the FDA warning on urethral sling placement for stress urinary incontinence (SUI). We sought to determine insertion and revision rates of urethral sling across time and among general gynecologists, urologists, and female pelvic medicine and reconstructive surgery (FPMRS) trained physicians using a statewide database.
METHODS: The New York Statewide Planning and Research Cooperative System (SPARCS) is an all payer reporting system that collects physician and patient data. Data on sling implantations for SUI performed by NY physicians from 2005 to 2015 were extracted using CPT codes. Physician board certification data was collected based on NY license numbers. Pre-2011 was defined as 2007-2010 and post-2011 was defined as 2012-2015. RESULTS: 54,151 sling operations were identified, of which 2,472 were revisions. Total urethral sling placements decreased by 40.9% from 2011 to 2015. After 2011, the proportion of slings placed by non-FPMRS physicians decreased (70.2% to 58.3%).The total number of sling revisions remained relatively stable from 2011 to 2015. In this time, FPMRS providers began to perform the majority of revisions (46.8% to 57.8%). Since the FDA warning, average time between sling implant and revision decreased for both non-FPMRS and FPMRS providers (non-FPMRS: 72 mo. to 24 mo., FPMRS: 64 mo. to 23 mo., p<0.001).
CONCLUSIONS: Since the FDA warning, utilization of the urethral sling by non-FPMRS physicians for SUI has greatly decreased, with an increasing proportion of procedures by FPMRS physicians. Similarly, the proportion of sling revisions by FPMRS physicians has increased. Decreased time between sling implant and revision may reflect more aggressive surveillance of patients in response to the FDA and/or patient driven concerns.
